Type II (non-insulin-dependent) diabetes mellitus is a polygenic disorder characterized by insulin secretory defects or insulin resistance or both, but the precise underlying genetic factors are largely not known. Recently, mutations and polymorphisms of transcription factors expressed in pancreatic endocrine cells have been reported to be related to the development of diabetes mellitus. Hepatocyte nuclear factor-1a (HNF1a), HNF-4a and insulin promoter factor-1 (IPF-1) genes have been reported to be associated with MODY (maturity-onset diabetes of the young) [1] .
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Variants of IPF-1 [2, 3] and NeuroD [4] have also been reported to be related to the development of Type II diabetes.
Neurogenins are a set of basic helix-loop-helix (bHLH) transcription factors which are essential for the determination of neuronal tissues during embryonic development. Neurogenin 1 and neurogenin 2 are essential for the determination of sensory lineages in the peripheral nervous system. Neurogenin 3 (ngn3) is expressed not only in restricted domains of the developing central nervous system but also in the endocrine precursor cells of the pancreas [5] . It has been shown that ngn3-deficient mice lack pancreatic endocrine cells and die of postnatal diabetes [6] . It has therefore been suggested that ngn3 is essential for the development of pancreatic endocrine cells. We thus considered the possibility that ngn3 could be a candidate gene responsible for Type II diabetes. 
Subjects and methods
Subjects. Subjects with Type II diabetes were recruited from the Department of Metabolic Diseases, University of Tokyo Hospital, and control subjects were recruited from the Hiroshima Atomic Bomb Casualty Council Health Management Center. All the subjects enrolled in this study were ethnic Japanese. Type II diabetes was diagnosed according to the criteria of the World Health Organisation [7] . Control subjects had to meet all of the following three criteria: 1) age of more than 60 years, 2) HbA 1 c of less than 6.0 %, 3) no family history of Type II diabetes. The characteristics of the patients with Type II diabetes and control subjects are shown in Table 1 . A total of 81 of the diabetic patients and 20 of the control subjects were screened for polymorphisms from among the 197 patients with Type II diabetes and 216 control subjects recruited for the association study. All the participants gave their written informed consent before participating in the study, and the protocol was approved by the ethics committee of the University of Tokyo Hospital.
Nucleotide numbering. The A of ATG of the initiator Met codon of the sequence is denoted as nucleotide + 1.
Screening for mutations in the ngn3 gene. We conducted direct sequencing of the entire coding region, 5'-and 3'-untranslated regions (UTR), as well as intron 1 of ngn3 in 81 Japanese patients with Type II diabetes and 20 control subjects, based on the sequence reported in GenBank (accession number AJ133 776). We also performed direct sequencing of 2.4 kb of upstream region of ngn3 in 20 Japanese patients with Type II diabetes and 20 control subjects, based on the draft sequence reported in GenBank (accession number AC011 010). These regions of the ngn3 gene were amplified by polymerase chain reaction (PCR) using the nine sets of primers. The segments were amplified using specific primers as follows: segment 1 sec at 72 C were run, followed by an additional 7 min at 72 C after the last cycle. The PCR products were purified and sequenced on an ABI PRISM 310 Genetic Analyzer using the BigDye Terminator (Perkin Elmer, Foster City, Calif., USA).
Allelic frequency study. Allelic frequency study of the Ser199-Phe (596C/T) and the ±983C/T polymorphisms was carried out by restriction fragment length polymorphism analysis. For the Ser199Phe (596C/T) polymorphism, PCR products of segment 2 c were digested overnight with Mbo II at 37 C, leaving a 401-bp fragment for the T allele, and 234-and 167-bp fragments for the C allele. For the ±983C/T polymorphism, genotyping was performed by PCR products using primers as follows: forward, 5'-TGGGATCTATGGGGGTGGGGTTC-TAAGTGC-3', reverse, 5'-AGAGAGATCCTGCCTATG-TCCCTTCCATGC-3'. Each primer contained one nucleotide mismatch (underlined), which made it possible to use the restriction enzyme Hha I for the detection of the ±983C/T polymorphism. PCR was carried out in a 20-ml reaction mixture described above, added with 5 % DMSO. For this primer set, initial denaturation at 94 C for 5 min, 35 cycles of 30 sec at 94 C, 30 sec at 65 C were run, followed by an additional 7 min at 72 C after the last cycle. PCR products were digested overnight with Hha I at 37 C, leaving a 96-and 29-bp fragments for the C allele, and 125-bp fragment for the T allele. Genotypes were determined by electrophoresis on 3 % agarose gel and ethidium bromide staining. The ±43insCA and ±1822G/A polymorphisms were screened by direct sequencing, because these polymorphisms did not alter any restriction enzyme recognition site.
Results
We identified two polymorphisms of the ngn3 gene, a substitution of C to T at position 596, which was a missense variant which converts codon 199 Ser to Phe, and an insertion of CA at position ±43, which lies in intron 1, at a position 42-bp upstream of the junction between intron 1 and exon 2. We also identified two polymorphisms in the upstream region, a substitution of C to T at position ±983 and a substitution of G to A at position ±1822. The allelic frequencies of these polymorphisms are shown in Table 2 . The frequencies of both the alleles were in HardyWeinberg equilibrium. There is linkage disequilibri- [8, 9] in Type II diabetic patients of Ser199Phe and ±43insCA, 0.76; Ser199Phe and ±983C/T, 0.72; Ser199Phe and ±1822G/A, ±0.64; ±43insCA and ±983C/T, 0.97; ±43in-sCA and ±1822G/A, ±0.51; and ±983C/T and ±1822G/ A, ±0.46. Similar D' values were observed in control subjects. Analysis of the distribution of the two alleles using a simple chi-squared (c 2 ) test revealed no association between these genotypes and Type II diabetes. Among the diabetic patients, we did not find any significant difference in terms of treatment between those with and without the polymorphisms. The allelic frequencies of the Ser199Phe polymorphism in patients who were treated with insulin, oral hypoglycaemic agents and diet alone were 0.736, 0.727 and 0.691 for Phe, respectively, those of the ±43insCA polymorphism in the same groups of patients were 0.934, 0.912 and 0.894 for the insertion allele, respectively, those of the ±983C/T polymorphism in the same groups of patients were 0.943, 0.912 and 0.904 for the C allele, respectively, and those of the ±1822G/A polymorphism in the same groups of patients were 0.538, 0.526 and 0.532 for the G allele, respectively.
We also identified differences between the sequences reported in GenBank and those in our subjects at three sites in the coding region. Although the nucleotides at positions 128, 292 and 493 reported in GenBank were C, G and C, respectively, our data demonstrated that these corresponding nucleotides were G, A and T, respectively, in all of the 81 patients with Type II diabetes and 20 control subjects examined by us.
Discussion
We screened for variability of the ngn3 gene in 197 patients with Type II diabetes and 216 control subjects. This showed one missense variant at codon 199 (Ser®Phe) and one insertion-deletion variant in intron 1. We also identified two polymorphisms in the upstream region. The allelic frequencies of these polymorphisms were not statistically significantly different between Type II diabetic patients and control subjects. The variants were also not associated with treatments among diabetic patients. We concluded that the Ser199Phe, ±43insCA, ±983C/A and ±1822G/ A polymorphisms of ngn3 are not significantly related to either the development or the severity of Type II diabetes.
The differences between the sequences reported in GenBank and those in our subjects were associated with changes of amino acids. One of these changes was present at the codon 98, which was in the junctional region between the basic region and the helix 1 region of the bHLH domain [5] . We cannot exclude the possibility that the differences between our data and those submitted data in GenBank reflect the differences between ethnic groups.
We identified four polymorphisms of the ngn3 gene and determined that these polymorphisms were not significantly associated with Type II diabetes in the Japanese subjects. We cannot exclude the possibility that these polymorphisms contribute to the development of Type II diabetes in combination with other factors. Rare sequence variants other than those presented by us here could play a part in the pathogenesis of MODY (maturity-onset diabetes of the young)-like diabetes, idiopathic Type I diabetes or neurological disorders, since ngn3 is involved in the development of both of the endocrine cells of the pancreas and the nervous system [5] . These polymorphisms could be useful for genetic studies by the haplotype analysis approach. Further studies are needed to evaluate the possible biological impact of variants of the ngn3 gene on the pathogenesis of diabetes.
